Taisho Pharmaceutical Co., Ltd.

Kosuke Kanuma

Tsuyoshi Shibata

Atsuro Nakazato

Thuy-Anh Tran

Toshihito Kumagai

Kazunari Sakagami

Nigel Robert Arnold Beeley

Yoshinori Sekiguchi

Bryan Aubrey Kramer

Madoka Kawamura

Naoki Miyakoshi

Katsunori Omodera

PROBLEM To provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action. SOLUTION A compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I). 

7-piperidinoalkyl-3, 4-Dihydroquinolone derivative

The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.

MCH receptor antagonists

Dicarboxylic acid derivatives

Growing community of inventors

Toshima-ku, Japan

Kosuke Kanuma